


The stand of the stand stand stand stand the stand of the stand stand stand stand stand stand stands



total time period (0-35 h)	CCTD (> 22µmol/l)	CK (> 100 U/I)	CK-MB (≥ 6% of CK)	Myo (> 90 ng/ml)	cTnl/T (cTnl > 1,5 μg/l)
sensitivity	%9.96	57.1%	57.1 %	%2'09	69.5 %
specificity	92.8 %	71.4 %	100 %	64.2 %	92.8 %
positive predictive value	% 9.96	%0.0%	100%	77.2 %	94.7 %
negative predictive value	92.8 %	45.4 %	53.8 %	45.0%	52.0%
diagnostic efficiency   95.4 %	95.4 %	61.9 %	71.4 %	61.9%	70.4 %

Fig. 3: Diagnostic valency of choline, choline derivatives, and trimethyl ammonium derivatives (CCTD) compared with other infarction markers during total time period (0-35 h).

Number of samples (n) infarction group: CCTD n=30, CK/CK-MB/myoglobin (Myo) n=28, troponin I/T (cTnI/T) n=23; control group: all markers

n=14

early phase of AMI (0-6 h)	ССТD (> 22µmol/l)	CK (> 100 U/l)	CK-MB (≥ 6% of CK)	Myo (> 90 ng/ml)	cTnl/T (cTnl > 1,5 μg/l)
sensitivity	% 001	37.5 %	37.5 %	62.5 %	50.0%
specificity	92.8 %	71.4 %	100 %	64.2 %	92.8 %
positive predictive value	94.7 %	% 0.09	100 %	% 9.99	87.5 %
negative predictive value	100%	% 0.0 %	58.3 %	% 0.09	65.0%
diagnostic efficiency	% 8.96	53.3 %	% 9.99	63.3 %	71.4%

Fig. 4: Diagnostic valency of choline, choline derivatives, and trimethyl ammonium derivatives (CCTD) compared with other infarction markers during the early phase of the AMI (0-6 h).

Number of samples (n) infarction group: CCTD n=18, CK/CK-MB/myoglobin (Myo) n=16, troponin I/T (cTnI/T) n=14; control group: all markers

early phase of AMI	CCTD	CK	CK-MB	Myo	cTnl/T
(0-3 h)	(> 22µmol/I)	(> 100 U/I)	(≥ 6% of CK)	(> 90 ng/ml)	(cTnl > 1,5 μg/l)
sensitivity	100%	12.5 %	12.5 %	50.0%	28.5 %
specificity	92.8 %	71.4%	100 %	64.2 %	92.8 %
positive predictive value	88.8 %	20.0 %	100 %	44.4 %	66.6%
negative predictive value	100%	58.8 %	% 9.99	69.2 %	72.2 %
diagnostic efficiency   95.4 %	95.4 %	% 0.0 %	68.1%	29.0%	71.4 %

Fig. 5: Diagnostic valency of choline, choline derivatives, and trimethyl ammonium derivatives (CCTD) compared with other infarction markers during the early phase of the AMI (0-3 h).

Number of samples (n) infarction group: CCTD n=8, CK/CK-MB/myoglobin (Myo) n=8, troponin I/T (cTnI/T) n=7; control group: all markers

1-1

late phase of AMI	CCTD	CK	CK-MB	Myo	cTnl/T
(7-35 h)	(> 22µmol/l)	(> 100 U/I)	(≥ 6% of CK)	(lm/gn 06 <)	(cTnl > 1,5 μg/l)
sensitivity	91.6%	83.3 %	83.3 %	58.3 %	100%
specificity	92.8 %	71.4 %	100 %	64.2 %	92.8 %
positive predictive	% 9.16	71.4 %	100 %	58.3 %	% 0.06
negative predictive value	92.8 %	83.3 %	87.5 %	64.2 %	100%
diagnostic efficiency 92.3 %	92.3 %	% 6.9 %	92.3 %	61.5%	% 9.69

Fig. 6: Diagnostic valency of choline, choline derivatives, and trimethyl ammonium derivatives (CCTD) compared with other infarction markers during the late phase of the AMI (7-35 h).

Number of samples (n) infarction group: CCTD n=12, CK/CK-MB/myoglobin (Myo) n=12, troponin I/T (cTnI/T) n=9; control group: all markers